Aquestive Resubmits FDA Application for Anaphylm After Addressing Packaging Concerns
Event summary
- Aquestive Therapeutics resubmitted its NDA for Anaphylm (dibutepinephrine) sublingual film on September 17, 2026, addressing FDA's Complete Response Letter from January 2026.
- The resubmission includes positive human factors and pharmacokinetic study results, reducing median pouch-opening time from 17 seconds to 3 seconds.
- Anaphylm is a needle-free, highly portable treatment for Type I allergic reactions, including anaphylaxis.
- FDA will determine the resubmission classification and review timeline following its initial review.
The big picture
Aquestive's resubmission of Anaphylm's NDA reflects a strategic pivot to address FDA concerns about packaging and administration. The sublingual film's design aims to overcome barriers in epinephrine access and administration, potentially disrupting the anaphylaxis treatment market. The FDA's response will be critical in determining the product's commercial viability.
What we're watching
- Regulatory Timing
- The pace at which the FDA reviews and classifies the resubmission will determine the approval timeline for Anaphylm.
- Market Differentiation
- Whether Anaphylm's needle-free, portable design can capture market share from existing epinephrine auto-injectors.
- Commercial Strategy
- How Aquestive's allergist-first launch strategy will impact adoption if Anaphylm gains FDA approval.
Related topics